WO2024141784A3 - Vaccins et compositions à protection large contre les bètacoronavirus - Google Patents

Vaccins et compositions à protection large contre les bètacoronavirus Download PDF

Info

Publication number
WO2024141784A3
WO2024141784A3 PCT/IB2023/000780 IB2023000780W WO2024141784A3 WO 2024141784 A3 WO2024141784 A3 WO 2024141784A3 IB 2023000780 W IB2023000780 W IB 2023000780W WO 2024141784 A3 WO2024141784 A3 WO 2024141784A3
Authority
WO
WIPO (PCT)
Prior art keywords
betacoronavirus
vaccines
compositions
broadly protective
rbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2023/000780
Other languages
English (en)
Other versions
WO2024141784A2 (fr
Inventor
Tushar Ranjan MOHARANA
Soham Govindarajan SANKARAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Popvax Pvt Ltd
Original Assignee
Popvax Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Popvax Pvt Ltd filed Critical Popvax Pvt Ltd
Publication of WO2024141784A2 publication Critical patent/WO2024141784A2/fr
Publication of WO2024141784A3 publication Critical patent/WO2024141784A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de manière générale des acides nucléiques codant pour un polypeptide. Le polypeptide comprend un domaine de liaison de récepteur (RBD), un peptide de fusion ou une hélice à tige, ou une combinaison de ceux-ci. Le RBD, le peptide de fusion ou l'hélice à tige sont obtenus ou dérivés d'un bêtacoronavirus.
PCT/IB2023/000780 2022-12-29 2023-12-28 Vaccins et compositions à protection large contre les bètacoronavirus Ceased WO2024141784A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263435980P 2022-12-29 2022-12-29
US63/435,980 2022-12-29

Publications (2)

Publication Number Publication Date
WO2024141784A2 WO2024141784A2 (fr) 2024-07-04
WO2024141784A3 true WO2024141784A3 (fr) 2024-09-26

Family

ID=90364119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/000780 Ceased WO2024141784A2 (fr) 2022-12-29 2023-12-28 Vaccins et compositions à protection large contre les bètacoronavirus

Country Status (1)

Country Link
WO (1) WO2024141784A2 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592602A (zh) * 2020-02-10 2020-08-28 中国科学院微生物研究所 一种β冠状病毒抗原、其制备方法和应用
WO2021159040A2 (fr) * 2020-02-07 2021-08-12 Modernatx, Inc. Vaccins à domaine arnm anti sars-cov-2
WO2021159130A2 (fr) * 2020-05-15 2021-08-12 Modernatx, Inc. Vaccins a arn de coronavirus et procédés d'utilisation
WO2021168875A1 (fr) * 2020-02-24 2021-09-02 中山大学 Sous-unité nanovaccinale à double région de protéine s du nouveau coronavirus à base de ferritine d'helicobacter pylori
WO2022096899A1 (fr) * 2020-11-09 2022-05-12 Autolus Limited Protéines de spicule virale et fusion de celles-ci
WO2022197624A1 (fr) * 2021-03-15 2022-09-22 Modernatx, Inc. Utilisation thérapeutique de vaccins à domaine arnm de sars-cov-2
US20220401550A1 (en) * 2020-02-13 2022-12-22 Institiut Pasteur NUCLEIC ACID VACCINE AGAINST THE SARS-CoV-2 CORONAVIRUS
WO2022262142A1 (fr) * 2021-06-18 2022-12-22 国药中生生物技术研究院有限公司 Vaccin à base de protéine rbd tripolymère de sars-cov-2 recombinante capable de générer une activité de neutralisation croisée à large spectre, son procédé de préparation et son utilisation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
WO2002087541A1 (fr) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Formulations a base de lipides pour transfert genique
EP1664316B1 (fr) 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Composes lipidiques modifies avec du polyethyleneglycol et utilisations de ces composes
CA2569664C (fr) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans des lipides
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
WO2009086558A1 (fr) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Compositions et procédés améliorés pour la délivrance d'acides nucléiques
CA2721333C (fr) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Nouvelles formulations lipidiques pour l'administration d'acides nucleiques
CA2740000C (fr) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Lipides amines ameliores et procedes d'administration d'acides nucleiques
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
CA2769670C (fr) 2009-07-31 2018-10-02 Ethris Gmbh Arn ayant une combinaison de nucleotides non modifies et modifies pour l'expression proteique
EP3494963A1 (fr) 2009-12-18 2019-06-12 The University of British Columbia Procédés et compositions d'administration d'acides nucléiques
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
HRP20230209T1 (hr) 2015-10-28 2023-04-14 Acuitas Therapeutics Inc. Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
EP3585886B1 (fr) 2017-02-27 2023-11-22 Translate Bio, Inc. Synthèse à grande échelle d'arn messager
US20190314291A1 (en) 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
WO2020168466A1 (fr) 2019-02-19 2020-08-27 Stemirna Therapeutics Co., Ltd. Nucléoside modifié et procédés de synthèse associés
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
WO2022082001A1 (fr) 2020-10-15 2022-04-21 Translate Bio, Inc. Synthèse à grande échelle d'arn messager

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021159040A2 (fr) * 2020-02-07 2021-08-12 Modernatx, Inc. Vaccins à domaine arnm anti sars-cov-2
CN111592602A (zh) * 2020-02-10 2020-08-28 中国科学院微生物研究所 一种β冠状病毒抗原、其制备方法和应用
US20220401550A1 (en) * 2020-02-13 2022-12-22 Institiut Pasteur NUCLEIC ACID VACCINE AGAINST THE SARS-CoV-2 CORONAVIRUS
WO2021168875A1 (fr) * 2020-02-24 2021-09-02 中山大学 Sous-unité nanovaccinale à double région de protéine s du nouveau coronavirus à base de ferritine d'helicobacter pylori
WO2021159130A2 (fr) * 2020-05-15 2021-08-12 Modernatx, Inc. Vaccins a arn de coronavirus et procédés d'utilisation
WO2022096899A1 (fr) * 2020-11-09 2022-05-12 Autolus Limited Protéines de spicule virale et fusion de celles-ci
WO2022197624A1 (fr) * 2021-03-15 2022-09-22 Modernatx, Inc. Utilisation thérapeutique de vaccins à domaine arnm de sars-cov-2
WO2022262142A1 (fr) * 2021-06-18 2022-12-22 国药中生生物技术研究院有限公司 Vaccin à base de protéine rbd tripolymère de sars-cov-2 recombinante capable de générer une activité de neutralisation croisée à large spectre, son procédé de préparation et son utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGUER PAULA M ET AL: "Covalent coupling of Spike's receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2", SCIENTIFIC REPORTS, vol. 12, no. 1, 22 January 2022 (2022-01-22), US, XP093170865, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758758/pdf/41598_2021_Article_3675.pdf> DOI: 10.1038/s41598-021-03675-0 *
DAI LIANPAN ET AL: "A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS", CELL, ELSEVIER, AMSTERDAM NL, vol. 182, no. 3, 28 June 2020 (2020-06-28), pages 722 - 733, XP086239965, ISSN: 0092-8674, [retrieved on 20200628], DOI: 10.1016/J.CELL.2020.06.035 *
SHAFQAT AREEZ ET AL: "SARS-CoV-2 epitopes inform future vaccination strategies", FRONTIERS IN IMMUNOLOGY, vol. 13, 25 November 2022 (2022-11-25), Lausanne, CH, XP093170873, ISSN: 1664-3224, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732895/pdf/fimmu-13-1041185.pdf> DOI: 10.3389/fimmu.2022.1041185 *

Also Published As

Publication number Publication date
WO2024141784A2 (fr) 2024-07-04

Similar Documents

Publication Publication Date Title
AU2019311658A8 (en) Novel hyaluronidase variants and pharmaceutical composition comprising the same
CA2837395C (fr) Composition immunogene comprenant une proteine de fusion de toxine a et de toxine b de clostridioides difficile
WO2020193688A3 (fr) Compositions immunogènes et vaccins comprenant des peptides et des protéines du virus de la peste porcine africaine et leurs utilisations
WO2007106476A3 (fr) Compositions et procédés pour renforcer l&#39;immunogénicité d&#39;antigènes
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
NZ592611A (en) A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
WO2021198706A3 (fr) Vaccins contre le coronavirus
MX2023009995A (es) Composiciones que incluyen adyuvantes de sbi y metodos para usarlos.
WO2007011904A3 (fr) Vaccins recombinants contre la grippe
EP1651166B8 (fr) Polypeptides pour l&#39;induction d&#39;une reponse immunitaire de protection contre le staphylococcus aureus
WO2020243706A8 (fr) Vecteur d&#39;herpesvirales recombinant
WO2002038742A3 (fr) Dipeptidylpeptidases et leurs procedes d&#39;utilisation
WO2021084276A3 (fr) Produit de synthèse de facteur viii
WO2010126156A3 (fr) Variants de protéase alcaline
WO2004035618A3 (fr) Acides nucleiques codant pour le facteur d&#39;adhesion du streptocoque du groupe b, facteur d&#39;adhesion du streptocoque du groupe b et autres utilisations correspondantes
EP4663009A3 (fr) Biosynthèse d&#39;anthocyanine dans des plantes de carotte
WO2020108629A8 (fr) Polypeptide rdp1, son procédé de fabrication et son utilisation
NZ586074A (en) LCLRP peptides, constructs and uses thereof
NZ590011A (en) Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof
WO2024141784A3 (fr) Vaccins et compositions à protection large contre les bètacoronavirus
WO2003090667A3 (fr) Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16
EP4282960A3 (fr) Lipase modifiée et son utilisation
WO2008012689A3 (fr) Dérivés citokine
MX2021013702A (es) Subunidad s2 modificada de la proteina de espicula de coronavirus.
ZA202307543B (en) Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23864110

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23864110

Country of ref document: EP

Kind code of ref document: A2